Study shows ResApp Health algorithms deliver high accuracy

Company News

by Rachael Jones

Digital health smartphone company for respiratory disease, ResApp Health (ASX:RAP) has announced positive top-line results from its Australian Breathe Easy adult clinical study.

ResApp’s smartphone-based algorithms were found to accurately diagnose all respiratory diseases included in the study: lower respiratory tract disease, pneumonia, asthma exacerbations, chronic obstructive pulmonary disease (COPD).

The study recruited 979 participants.

As many as 339 million people are estimated to have asthma.

The ability to identify a worsening of asthma symptoms due to infection or irritants, is an important part of effective asthma management plans.

Shares in ResApp Health (ASX:RAP) closed flat at 12.5 cents on Thursday 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.